Contineum Therapeutics, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Contineum Therapeutics reported Q2 2026 net loss of $15.2M (vs. $16.0M in Q2 2025) with cash/securities of $236.6M providing runway through mid-2029. The company initiated dosing in PROPEL-IPF Phase 2 trial (324 IPF patients, 55+ sites across 8 countries evaluating PIPE-791) and Johnson & Johnson completed enrollment of 107 participants in MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 for major depressive disorder. Continuum reduced its research workforce and eliminated its Chief Scientific Officer position, streamlining discovery programs to focus on inflammatory and fibrotic diseases.
Why this rating
Company-stage advancement is positive; trial progress and extended runway (2.75 years) offset by workforce reduction, CSO loss, and heavy pipeline concentration in two early-stage assets.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.